2-acetylthiomethyl-3-(4-methylbenzoyl)propionic acid
| Title | Journal |
|---|---|
| S-oxidation of S-methyl-esonarimod by flavin-containing monooxygenases in human liver microsomes. | Xenobiotica; the fate of foreign compounds in biological systems 20031201 |
| Synthesis and structure-activity relationships of 5-phenylthiophenecarboxylic acid derivatives as antirheumatic agents. | Bioorganic & medicinal chemistry 20031103 |
| A practical procedure for the synthesis of esonarimod, (R,S)-2-acetylthiomethyl-4-(4-methylphenyl)-4-oxobutanoic acid, an antirheumatic agent (part 1). | Chemical & pharmaceutical bulletin 20021001 |
| Synthesis and antirheumatic activity of the metabolites of esonarimod. | Bioorganic & medicinal chemistry 20020801 |
| Formation of a disulfide protein conjugate of the SH-group-containing metabolite (M-I) of esonarimod (KE-298) and its elimination in rats. | The Journal of pharmacy and pharmacology 20020401 |
| Effects of a new anti-rheumatic drug KE-298 and its active metabolite: KE-758 on secretion of thioredoxin and on the level of intracellular glutathione in human monocytes and T cells. | Molecular immunology 20020201 |
| KE-758, an active metabolite of the new anti-rheumatic drug KE-298, suppresses production of tumor necrosis factor-alpha and interleukin-1 beta in THP-1, a human monocyte cell line. | Drugs under experimental and clinical research 20020101 |
| Expression of membrane-type 1 matrix metalloproteinase in rheumatoid synovial cells. | Clinical and experimental immunology 20011001 |
| New disease-modifying antirheumatic drug 2 acetylthiomethyl-4-(4-methylphenyl)-4-oxobutanoic acid (KE-298) selectively augments activation-induced T cell death. | The Journal of laboratory and clinical medicine 20010701 |
| Stereoselectivity and species difference in plasma protein binding of KE-298 and its metabolites. | Biological & pharmaceutical bulletin 20010701 |
| KE-298 and its active metabolite KE-758 suppress nitric oxide production by murine macrophage cells and peritoneal cells from rats with adjuvant induced arthritis. | The Journal of rheumatology 20010601 |
| Effects of KE-758; an active metabolite of the new anti-rheumatic drug KE-298, D-penicillamine, bucillamine and auranofin on the proliferation of murine lymphocytes, and the production of nitric oxide by murine macrophages. | International immunopharmacology 20010501 |
| The new antirheumatic drug KE-298 suppresses monocyte chemoattractant protein (MCP)-1 and RANTES production in rats with adjuvant-induced arthritis and in IL-1beta-stimulated synoviocytes of patients with rheumatoid arthritis. | Rheumatology international 20010501 |